ArticleActa crystallographica. Section E, Crystallographic communications2016
Crystal structure of (4-cyano-pyridine-κN){5,10,15,20-tetrakis[4-(benzoyloxy)phenyl]porphyrinato-κ(4) N}zinc-4-cyano-pyridine (1/1).
Article in Acta crystallographica. Section E, Crystallographic communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effect of the coordination of π-acceptor 4-cyanopyridine ligand on the structural and electronic properties ofRSC advances · 2020Article
- Crystal structure of {4-[10,15,20-tris-(4-meth-oxy-phen-yl)porphyrin-5-yl]benzyl 2-diazo-acetato}-zinc(II).Acta crystallographica. Section E, Crystallographic communications · 2020Article
- Synthesis, crystal structure and characterizations of di-μ-cyanido-1:2κActa crystallographica. Section E, Crystallographic communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the title compound, [Zn(C72H44N4O8)(C6H4N2)]·C6H4N2 or [Zn(TPBP)(4-CNpy]·(4-CNpy) [where TPBP and 4-CNpy are 5,10,15,20-(tetra-phenyl-benzoate)porphyrinate and 4-cyano-pyridine, respectively], the Zn(II) cation is chelated by four pyrrole-N atoms of the porphyrinate anion and coordinated by a pyridyl-N atom of the 4-CNpy axial ligand in a distorted square-pyramidal geometry. The average Zn-N(pyrrole) bond length is 2.060 (6) Å and the Zn-N(4-CNpy) bond length is 2.159 (2) Å. The zinc cation is displaced by 0.319 (1) Å from the N4C20 mean plane of the porphyrinate anion toward the 4-cyano-pyridine axial ligand. This porphyrinate macrocycle exhibits major saddle and moderate ruffling and doming deformations. In the crystal, the [Zn(TPBP)(4-CNpy)] complex mol-ecules are linked together via weak C-H⋯N, C-H⋯O and C-H⋯π inter-actions, forming supra-molecular channels parallel to the c axis. The non-coordinating 4-cyano-pyridine mol-ecules are located in the channels and linked with the complex mol-ecules, via weak C-H⋯N inter-actions and π-π stacking or via weak C-H⋯O and C-H⋯π inter-actions. The non-coordinating 4-cyano-pyridine mol-ecule is disordered over two positions with an occupancy ratio of 0.666 (4):0.334 (4).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.